Johnson & Johnson earnings top Wall Street estimates once again as strong pharmaceutical sales growth, led primarily by new drugs, helped offset negative currency translation and the loss of revenue from divested operational segments.
Johnson & Johnson earnings top Wall Street estimates once again as strong pharmaceutical sales growth, led primarily by new drugs, helped offset negative currency translation and the loss of revenue from divested operational segments.